Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OP-3136

Small molecule · Inhibitor of KAT6A (MOZ; MYST3) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B) · developed by Olema Pharmaceuticals

Phase 1 Most advanced trial
OLMA Developer
1 Registered trials

What is OP-3136?

OP-3136 is an orally bioavailable inhibitor of the histone acetyltransferases KAT6A and KAT6B, which binds these enzymes and blocks acetylation of histones and other substrates. It is being studied in breast cancer, non-small cell lung cancer, and castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
KAT6A (MOZ; MYST3) (KAT6A), KAT6B (MORF; MOZ2; MYST4) (KAT6B)
Mechanism
Inhibitor of KAT6A (MOZ; MYST3) (KAT6A) and KAT6B (MORF; MOZ2; MYST4) (KAT6B)
Pathways
histone acetylation, gene expression regulation, cell cycle regulation
Therapy area
Oncology
Developer
Olema Pharmaceuticals, Inc. (OLMA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06784193 Phase 1 Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) Recruiting OLMA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)FulvestrantMetastatic Breast CancerPalazestrant

Other drugs acting on KAT6A / KAT6B

More from Olema Pharmaceuticals

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OLMA page.

Follow OLMA, the company behind OP-3136

See OLMA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OLMA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.